278 related articles for article (PubMed ID: 3041925)
41. Interleukin-2 and lymphokine activated killer cells: promises and cautions.
Glassman AB
Ann Clin Lab Sci; 1989; 19(1):51-5. PubMed ID: 2644890
[TBL] [Abstract][Full Text] [Related]
42. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.
Mulé JJ; Smith CA; Rosenberg SA
J Exp Med; 1987 Sep; 166(3):792-7. PubMed ID: 3498002
[TBL] [Abstract][Full Text] [Related]
43. Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy.
Muul LM; Nason-Burchenal K; Carter CS; Cullis H; Slavin D; Hyatt C; Director EP; Leitman SF; Klein HG; Rosenberg SA
J Immunol Methods; 1987 Aug; 101(2):171-81. PubMed ID: 3611795
[TBL] [Abstract][Full Text] [Related]
44. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
Rosenberg SA; Lotze MT; Yang JC; Topalian SL; Chang AE; Schwartzentruber DJ; Aebersold P; Leitman S; Linehan WM; Seipp CA
J Natl Cancer Inst; 1993 Apr; 85(8):622-32. PubMed ID: 8468720
[TBL] [Abstract][Full Text] [Related]
45. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
[TBL] [Abstract][Full Text] [Related]
46. Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells.
Sugarbaker PH; Matthews W; Steller EP; Eggermont AM
J Biol Response Mod; 1987 Aug; 6(4):430-45. PubMed ID: 3498012
[TBL] [Abstract][Full Text] [Related]
47. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.
Lotze MT; Rosenberg SA
Immunobiology; 1986 Sep; 172(3-5):420-37. PubMed ID: 3100435
[TBL] [Abstract][Full Text] [Related]
48. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
Gregg EO; Gregg IC; Green I
Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
[TBL] [Abstract][Full Text] [Related]
49. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.
Schwarz RE; Vujanovic NL; Hiserodt JC
Cancer Res; 1989 Mar; 49(6):1441-6. PubMed ID: 2784350
[TBL] [Abstract][Full Text] [Related]
50. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
Rosenberg SA; Lotze MT; Muul LM; Chang AE; Avis FP; Leitman S; Linehan WM; Robertson CN; Lee RE; Rubin JT
N Engl J Med; 1987 Apr; 316(15):889-97. PubMed ID: 3493432
[TBL] [Abstract][Full Text] [Related]
51. Adoptive immunotherapy of cancer: accomplishments and prospects.
Rosenberg SA
Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
[TBL] [Abstract][Full Text] [Related]
52. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
53. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
Taguchi T; Domoto K
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
[TBL] [Abstract][Full Text] [Related]
54. Augmentation of lymphokine-activated killer cell activity in patients with gastrointestinal cancer.
Sedman PC; Ramsden CW; Brennan TG; Giles GR; Guillou PJ
Br J Surg; 1988 Jun; 75(6):591-4. PubMed ID: 3134974
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications.
Lotze MT; Custer MC; Bolton ES; Wiebke EA; Kawakami Y; Rosenberg SA
Hum Immunol; 1990 Jun; 28(2):198-207. PubMed ID: 2190952
[TBL] [Abstract][Full Text] [Related]
56. Interleukin 2 in cancer therapy.
Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
[TBL] [Abstract][Full Text] [Related]
57. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
Rosenberg SA; Spiess P; Lafreniere R
Science; 1986 Sep; 233(4770):1318-21. PubMed ID: 3489291
[TBL] [Abstract][Full Text] [Related]
58. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
Yoshida S; Tanaka R; Takai N; Ono K
Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
[TBL] [Abstract][Full Text] [Related]
59. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Shu SY; Chou T; Rosenberg SA
J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
[TBL] [Abstract][Full Text] [Related]
60. Sterile abscesses in glioma patients treated by intraparenchymal injection of lymphokine-activated killer cells and recombinant interleukin-2: case reports.
Atkinson LL; Merchant RE; Ghatak NR; Young HF
Neurosurgery; 1989 Nov; 25(5):805-10. PubMed ID: 2586734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
